Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Starling Oncology's operating margin for the twelve months ending Jun 30, 2026 was -4.4%. For fiscal 2025 it was -7.2%, against -15.3% the year before. The highest annual figure on record is -4.4% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -7.2% | +8.1 |
| FY2024 | Dec 31, 2024 | -15.3% | +8.5 |
| FY2023 | Dec 31, 2023 | -23.8% | +8.7 |
| FY2022 | Dec 31, 2022 | -32.5% | −9.9 |
| FY2021 | Dec 31, 2021 | -22.6% | −18.2 |
| FY2020 | Dec 31, 2020 | -4.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -2.9% | +6.5 |
| Q1 FY2026 | Mar 31, 2026 | -4.4% | +5.1 |
| Q4 FY2025 | Dec 31, 2025 | -4.9% | +7.0 |
| Q3 FY2025 | Sep 30, 2025 | -5.9% | +8.0 |
| Q2 FY2025 | Jun 30, 2025 | -9.4% | +7.2 |
| Q1 FY2025 | Mar 31, 2025 | -9.5% | +9.5 |
| Q4 FY2024 | Dec 31, 2024 | -11.9% | +5.9 |
| Q3 FY2024 | Sep 30, 2024 | -13.9% | +3.1 |
| Q2 FY2024 | Jun 30, 2024 | -16.6% | +2.0 |
| Q1 FY2024 | Mar 31, 2024 | -19.0% | +24.2 |
| Q4 FY2023 | Dec 31, 2023 | -17.8% | +17.3 |
| Q3 FY2023 | Sep 30, 2023 | -17.0% | +14.0 |
| Q2 FY2023 | Jun 30, 2023 | -18.6% | +11.4 |
| Q1 FY2023 | Mar 31, 2023 | -43.1% | −9.7 |
| Q4 FY2022 | Dec 31, 2022 | -35.1% | +43.0 |
| Q3 FY2022 | Sep 30, 2022 | -30.9% | −26.8 |
| Q2 FY2022 | Jun 30, 2022 | -30.0% | −27.8 |
| Q1 FY2022 | Mar 31, 2022 | -33.5% | −29.9 |
| Q4 FY2021 | Dec 31, 2021 | -78.1% | – |
| Q3 FY2021 | Sep 30, 2021 | -4.1% | – |
| Q2 FY2021 | Jun 30, 2021 | -2.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -3.6% | – |